Feasibility and outcomes of switching factor VIII therapies: post-hoc analysis of patients transitioning from older plasma-derived and first-generation recombinant factor VIII to newer third generation recombinant factor VIII replacement therapies within the Takeda factor VIII portfolio

Key Points

• The research explores the efficacy of switching from older factor VIII therapies to newer recombinant options.
• Post-hoc analysis of patients transitioning to rAHF-PEG
• Evaluation of bleeding outcomes
• Comparison to original trial results
• Improvements in bleeding outcomes after switching to rAHF-PEG
• Findings align with original trial results
• Support for transitioning between older and newer therapies